A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment

Andric, Marko; Dixit, Shreya; Robaei, Dana; Watchorn, Rosemary; Verma, Nitin

doi:10.4103/0301-4738.121133

Cited by 7 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eighty-nine percent of patients were reported to respond partially or fully to first-line therapy (30/45). One patient experienced a flare when corticosteroids were weaned, and again when hydroxychloroquine was introduced as a corticosteroid-sparing agent [ 35 ]. Ten patients went on to have second-line therapy or dose adjustments for their mAb-induced SCLE due to non-response or partial response.…”

Section: Resultsmentioning

confidence: 99%

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus

et al. 2020

View full text Add to dashboard Cite

Background Subacute cutaneous lupus erythematosus (S(CLE) lacks consensus diagnostic criteria and the pathogenesis is poorly understood. There are increasing reports of SCLE induced by monoclonal antibodies (mAbs), but there are limited data on the aetiology, clinical characteristics and natural course of this disease. Methods We devised a set of diagnostic criteria for SCLE in collaboration with a multinational, multispecialty panel. This systematic review employed a two-layered search strategy of five databases for cases of mAb-induced SCLE (PROSPERO registered protocol CRD42019116521). To explore the relationship between relative mAb use and the number of SCLE cases reported, the estimated number of mAb users was modelled from 2013 to 2018 global commercial data and estimated annual therapy costs. Results From 40 papers, we identified 52 cases of mAb-induced SCLE, occurring in a cohort that was 73% female and with a median age of 61 years. Fifty percent of cases were induced by anti-tumour necrosis factor (TNF)-ɑ agents. A median of three drug doses preceded SCLE onset and the lesions lasted a median of 7 weeks after drug cessation. Oral and topical corticosteroids were most frequently used. Of the licensed mAbs, adalimumab, denosumab, rituximab, etanercept and infliximab were calculated to have the highest relative number of yearly users based on global sales data. Comparing the number of mAb-induced SCLE cases with estimated yearly users, the checkpoint inhibitors pembrolizumab and nivolumab showed strikingly high rates of SCLE relative to their global use, but ipilimumab did not. Conclusion We present the first systematic review characterising mAb-induced SCLE with respect to triggers, clinical signs, laboratory findings, prognosis and treatment approaches. We identify elevated rates associated with the use of checkpoint inhibitors and anti-TNFɑ agents.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus

et al. 2020

View full text Add to dashboard Cite

show abstract

“…There have been reports of other VEGF biologic therapies that developed SCLE, such as bevacizumab and ranibizumab. 6 However, these medications are humanized antibodies against VEGF-A. There were no other confounding medications on his list.…”

Section: Short Communication Subacute Cutaneous Lupus Erythematosus A...mentioning

confidence: 99%